Abstract:Given past experience with widespread viral infections, for example influenza, we expected that SARS-CoV-2 would create a large number of de novo cases of immune thrombocytopenia (ITP). Perhaps a silver lining on the cloud of SARSCoV-2 is that for patients with ITP, the virus is not having a major effect, as evidenced by few reports of ITP in conjunction with SARS-CoV-2 infection. We performed a retrospective review of patients ≥18 years diagnosed with COVID-19 and ITP seen at New York Presbyterian–Weill Cornell Medicine (NYP-WCM) or Shandong Provincial Chest Hospital–Shandong University (SPCH-SDU) from February to August 2020. Ten patients from NYPWCM and two from SPCH-SDU were identified (Table I). The study was approved by the Institutional Review Board of NYP-WCM and the Medical Ethical Committee of SPCHSDU. There were 10 patients with pre-existing ITP and two with presumed new SARS-CoV-2-associated ITP (Table I). Patient 8 was diagnosed with ITP during hospitalization for COVID19 and Patient 10 developed isolated ITP six weeks following SARS-CoV-2 infection; neither had a prior history of thrombocytopenia. For those with pre-existing ITP, SARS-CoV-2 infections were managed as outpatients (n = 3), ER visits (n = 2), and hospitalizations (n = 5). During active COVID-19, five patients required ITP treatment for platelet nadirs of 8–33 9 10/l. Patient 7 received platelet transfusion, steroids and intravenous immunoglobulin (IVIg). Patients 1 and 9 received IVIg alone. Patient 1 had been on weekly romiplostim, twice daily mycophenolate mofetil (MMF) and IVIg as needed since 2017. She had fevers, fatigue, body aches and was ITP-Bleeding Assessment Tool: Skin 1 (petechiae), Mucosae 1 (epistaxis). Due to morbid obesity, limited mobility, and advanced age, she received weekly home infusions of IVIg 80 g for counts <10– 20 9 10/l. Patient 9, on prednisone 15 mg daily for platelets 20–30 9 10/l, was hospitalized at SPCH-SDU. He received IVIg 10 g daily for two days with platelet improvement from 18 to 28 9 10/l. Patient 8 received inpatient IVIg 15 g daily for three days, methylprednisolone 80 mg BID, and convalescent plasma for SARS-CoV-2-associated ITP with platelets increasing from 33 to 83 9 10/l. Several weeks following SARS-Cov-2 diagnosis, Patient 10 received IVIg with steroids for de novo ITP with platelet improvement from 6 to 82 9 10/l. Patient 7 had chronic ITP with platelets of 8 9 10/l requiring platelet transfusions. In the setting of multiorgan failure, he declined additional treatment and passed away. Two patients received steroids alone for exacerbations of known ITP during infection with SARS-CoV-2. Patient 11’s platelets dropped from 60–70 to 23 9 10/l two weeks after diagnosis. His platelets improved to 180 9 10/l on prednisone 20 mg daily. Patient 4’s platelets dropped from a baseline of 60–70 to 26 9 10/l. She received dexamethasone 40 mg for four days with platelets rising to 105 9 10/l. Five patients (Patients 2, 3, 5, 6, 12) did not modify their ITP treatment despite COVID-19. Three (Patients 2, 3, 6) were on treatment (eltrombopag, steroids, rituximab, respectively). Patient 5 was discharged from the ER with haematology follow-up for platelets 26 9 10/l and Patient 12 was diagnosed with SARS-Cov-2 on routine screening for caesarean section with platelets 94 9 10/l. Patients 3, 4, 6, 8 were hospitalized and received prophylactic anticoagulation with enoxaparin 40 mg SC daily (NYPWCM) or nadroparin 3 800 U SC daily (SPCH-SDU) without bleeding events. Patient 6 developed deep vein thrombosis (DVT) and pulmonary embolus (PE) despite prophylactic enoxaparin. He received therapeutic heparin and was discharged on apixaban. Patient 2 presented with a new headache due to cerebral venous sinus thrombosis and was discharged on apixaban. Treatments of ITP, ongoing or newly initiated, can impact the course and outcome of SARS-CoV-2. Thrombosis is a major concern in patients with SARS-CoV-2 infection and immunosuppression could worsen infection. The American Society of Hematology offers recommendations limited by data to expert opinion for ITP management in SARS-CoV-2 infection. IVIg is not immunosuppressive, rapidly increases platelets, and has anti-inflammatory effects. To avoid prolonged visits and SARS-CoV-2 exposures, home administration (like Patient 1) is useful. Steroids may risk increasing viral susceptibility early in infection; however, published reports and our own experience suggest steroid use does not often lead to worse outcomes in COVID-19. No consensus exists regarding increased severity of COVID-19 infection in patients who have received rituximab or are on other chronic immunosuppressants. Anti-CD20 agents impair humoral responses to de novo infections and vaccines for at least 4–6 months. We agree with avoiding immunosuppressives or rituximab during the COVID-19 pandemic pending reasonable alternatives. We also caution use of splenectomy due to increased thrombotic risk and risk of overwhelming sepsis. correspondence

Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with pre‐existing primary immune thrombocytopenia (ITP) in Spain

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

The Evolution of Preexisting Primary Immune Thrombocytopenia after COVID-19 Onset: A Nationally Representative, Prospective, Multicentre, Observational Study

Immune Thrombocytopenia During the COVID‐19 Pandemic

Immune Thrombocytopenia (ITP) in a Pediatric Patient Positive for SARS-CoV-2

Epidemiology, Treatment Patterns, and Cost Analysis of Immune Thrombocytopenia in Spain between 2014 and 2020: A Population-based Study

Emerging role of stem cell memory-like T cell (TSCM) in immune thrombocytopenia.

Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus

A Case of COVID-19-Induced Immune Thrombocytopenia (ITP) in an Adult Female: An Under-Recognized Emerging Phenomenon

COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report

Transient Complete Recovery of Chronic Refractory Idiopathic Thrombocytopenic Purpura after Treatment with Monoclonal Antibody Targeting SARS-CoV-2 Spike Protein

Immune thrombocytopenia in systemic lupus erythematosus: Prevalence, risk factors, and a novel predictive model for risk assessment

Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases

Advances in the pathophysiology of primary immune thrombocytopenia

Can COVID-19 Increase Platelet in Adult Immune Thrombocytopenia During the TPO-RA Administration? A Real-World Observational Study

Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine

Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation

Challenges in treating primary immune thrombocytopenia patients undergoing COVID-19 vaccination: A retrospective study

The Incidence and Characteristics of Thrombosis in Patients with Immune thrombocytopenia: A Retrospective Cohort Study

Acute Immune Thrombocytopenia (ITP) Following COVID-19 Vaccination in a Patient With Previously Stable ITP